Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Imugene stock

IMU.AX
AU000000IMU9
891460

Price

0.04
Today +/-
-0.00
Today %
-1.38 %

Imugene stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Imugene stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Imugene stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Imugene stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Imugene's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Imugene Stock Price History

DateImugene Price
12/27/20240.04 undefined
12/24/20240.04 undefined
12/23/20240.04 undefined
12/20/20240.04 undefined
12/19/20240.04 undefined
12/18/20240.04 undefined
12/17/20240.04 undefined
12/16/20240.04 undefined
12/13/20240.04 undefined
12/12/20240.04 undefined
12/11/20240.04 undefined
12/10/20240.04 undefined
12/9/20240.04 undefined
12/6/20240.04 undefined
12/5/20240.04 undefined
12/4/20240.04 undefined
12/3/20240.04 undefined
12/2/20240.04 undefined

Imugene Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Imugene, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Imugene from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Imugene’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Imugene. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Imugene’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Imugene’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Imugene’s growth potential.

Imugene Revenue, EBIT and net profit per share

DateImugene RevenueImugene EBITImugene Net Income
2030e1.32 B undefined0 undefined476.3 M undefined
2029e1.03 B undefined863.98 M undefined397.42 M undefined
2028e676.05 M undefined510.53 M undefined238.15 M undefined
2027e184.86 M undefined-3.97 M undefined23.29 M undefined
2026e48.82 M undefined-138.71 M undefined-75.13 M undefined
2025e4.71 M undefined-137.9 M undefined-107.66 M undefined
20240 undefined-140.73 M undefined-149.68 M undefined
20230 undefined-39.52 M undefined-37.91 M undefined
20220 undefined-37.7 M undefined-37.87 M undefined
20210 undefined-18.43 M undefined-18.46 M undefined
20200 undefined-10.74 M undefined-10.51 M undefined
20190 undefined-8.26 M undefined-7.78 M undefined
20181.94 M undefined-3.84 M undefined-3.93 M undefined
20171.2 M undefined-2.49 M undefined-2.51 M undefined
20161.56 M undefined-2.7 M undefined-2.73 M undefined
2015638,680 undefined-2.25 M undefined-2.44 M undefined
2014540,000 undefined-800,000 undefined-2.12 M undefined
2013210,000 undefined-1.53 M undefined-1.56 M undefined
2012290,000 undefined-1.11 M undefined-3.13 M undefined
20112.2 M undefined310,000 undefined420,000 undefined
2010360,000 undefined-1.71 M undefined-1.54 M undefined
20093.25 M undefined250,000 undefined650,000 undefined
2008410,000 undefined-2.15 M undefined-1.91 M undefined
2007480,000 undefined-2.56 M undefined-2.3 M undefined
2006370,000 undefined-2.44 M undefined-2.19 M undefined
2005390,000 undefined-2.12 M undefined-1.79 M undefined

Imugene Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
00000000000000000000000000.050.180.681.031.32
-------------------------1,100.00283.33267.3952.9628.05
-100.00------33.33-50.00----100.00100.00100.00------25.002.080.540.150.100.08
01,0000000000000000000000000000000
-40-1-2-1-2-2-10-10-3-1-2-2-2-2-3-7-10-18-37-37-149-107-7523238397476
---100.00-50.00100.00--50.00-----66.67100.00---50.00133.3342.8680.00105.56-302.70-28.19-29.91-130.67934.7866.8119.90
0.010.160.070.110.120.130.130.140.150.140.140.140.330.71.191.332.092.643.584.074.665.646.287.09000000
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Imugene Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Imugene is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                               
0.030.782.620.964.352.71.11.622.490.791.911.020.571.221.961.584.817.8219.0530.1129.4999.89153.1594.54
0.060.040000.0400.050.030.180.0500.050.010.541.311.221.914.174.176.5400.197.2
000000.540.530.20.30.520.470.2700.5100000.050.030.1212.7711.925.42
18000000000000000000000000
000.050.080.110000000.0300.010.020.020.020.10.160.190.171.110.45.87
0.270.822.671.044.463.281.631.872.821.492.431.320.621.752.522.916.059.8323.4234.4936.32113.77165.66113.03
0.610.020.020.020.010.020.010.0100000000000.230.160.470.860.681.7
000.480000000000000.020.020.020.050.080.120.250.222.41
00000000000000000000012.7712.110
1.5704.994.654.313.973.623.282.942.62.26016.876.66.66.67.067.0630.4634.8932.6930.4934.12
00000000000096000000000000
00000000000000000015.5915.5915.5934.919.31132.53
2.180.025.494.674.323.993.633.292.942.62.2601.966.876.66.626.627.087.3630.7135.4946.6143.5238.36
2.450.848.165.718.787.275.265.165.764.094.691.322.588.629.129.5412.6816.9130.7865.271.81160.38209.17151.4
                                               
26.7128.5236.758.1713.1813.1813.1814.9114.9114.9114.9114.9117.2824.2427.6830.4136.3444.2963.1292.8113.11230.79314.4370.31
000000000000000000000000
-26.94-27.72-29.31-2.73-4.53-6.72-8.48-10.24-9.58-11.12-10.7-13.83-15.39-17.51-19.95-22.55-24.94-28.81-35.83-45.09-60.19-96.78-129.42-252.25
000000000000000000012.112.14.74.650.19
000000000000000000000000
-0.230.87.445.448.656.464.74.675.333.794.211.081.896.737.737.8611.3915.4827.2959.8165.02138.7189.63118.25
0.80.050.420.550.360.730.420.380.270.170.070.120.10.150.320.660.230.341.481.010.764.512.345.97
0.470.010.0300000000000.0200000.860.390.711.181.614.83
0.1800.240.030.050.070.140.110.170.140.410.130.070.070.010.040.070.10.031.442.991.732.1418.5
000000000000000000000000
1.220000000000000.450.070000.060.060.110.180.190
2.670.060.690.580.410.80.560.490.440.310.480.250.170.690.40.690.30.442.422.94.567.616.2829.3
00000000000001.20.990.990.990.991.050.010.170.490.360.63
000000000000000000000000
0000000000000.5300000.020.012.492.170.990.993.21
0000000000000.531.20.990.990.9911.062.52.331.481.353.84
2.670.060.690.580.410.80.560.490.440.310.480.250.71.891.391.681.281.443.485.46.99.097.6333.14
2.440.868.136.029.067.265.265.165.774.14.691.332.598.629.129.5412.6816.9130.7865.271.92147.79197.25151.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Imugene provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Imugene's financial health and stability.

Assets

Imugene's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Imugene must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Imugene after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Imugene's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000000-37-37
00000000000000000000022
00000000000000000000000
000000000000000011144612
00000000000000000000083
00000000000000000000000
000000000000000000000-6-12
-2,0000-1,000-1,000-1,000-1,000-1,000-1,0000-1,0001,0000-1,000-1,000-2,000-3,000-2,000-4,000-7,000-10,000-13,000-30,000-31,000
0000000000000000000-1-500
0000000000000000000-1,000-5,00001,000
00000000000000000000001,000
00000000000000000000000
1,0000000000000000000000000
11305001000012336820241810888
21305001000002325718221710182
-------------------1.00-1.00--7.00-5.00
00000000000000000000000
-200-31-3-3-11-32-2-20-1-40-21-3-18339
-2.58-0.79-1.42-1.53-1.63-1.84-1.7-1.270.88-1.741.09-0.97-1.37-1.74-2.51-3.12-2.68-4.97-8.05-11.92-18.73-31.11-31.47
00000000000000000000000

Imugene stock margins

The Imugene margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Imugene. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Imugene.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Imugene's sales revenue. A higher gross margin percentage indicates that the Imugene retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Imugene's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Imugene's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Imugene's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Imugene. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Imugene's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Imugene Margin History

Imugene Gross marginImugene Profit marginImugene EBIT marginImugene Profit margin
2030e0 %0 %35.97 %
2029e0 %83.56 %38.44 %
2028e0 %75.52 %35.23 %
2027e0 %-2.15 %12.6 %
2026e0 %-284.14 %-153.9 %
2025e0 %-2,925.94 %-2,284.25 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %-198.58 %-203.28 %
20170 %-207.21 %-208.97 %
20160 %-172.9 %-174.56 %
20150 %-351.65 %-382.16 %
20140 %-148.15 %-392.59 %
20130 %-728.57 %-742.86 %
20120 %-382.76 %-1,079.31 %
20110 %14.09 %19.09 %
20100 %-475 %-427.78 %
20090 %7.69 %20 %
20080 %-524.39 %-465.85 %
20070 %-533.33 %-479.17 %
20060 %-659.46 %-591.89 %
20050 %-543.59 %-458.97 %

Imugene Stock Sales Revenue, EBIT, Earnings per Share

The Imugene earnings per share therefore indicates how much revenue Imugene has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Imugene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Imugene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Imugene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Imugene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Imugene Revenue, EBIT and net profit per share

DateImugene Sales per ShareImugene EBIT per shareImugene Earnings per Share
2030e0.18 undefined0 undefined0.06 undefined
2029e0.14 undefined0 undefined0.05 undefined
2028e0.09 undefined0 undefined0.03 undefined
2027e0.02 undefined0 undefined0 undefined
2026e0.01 undefined0 undefined-0.01 undefined
2025e0 undefined0 undefined-0.01 undefined
20240 undefined-0.02 undefined-0.02 undefined
20230 undefined-0.01 undefined-0.01 undefined
20220 undefined-0.01 undefined-0.01 undefined
20210 undefined-0 undefined-0 undefined
20200 undefined-0 undefined-0 undefined
20190 undefined-0 undefined-0 undefined
20180 undefined-0 undefined-0 undefined
20170 undefined-0 undefined-0 undefined
20160 undefined-0 undefined-0 undefined
20150 undefined-0 undefined-0 undefined
20140 undefined-0 undefined-0 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0.01 undefined-0.02 undefined
20110.02 undefined0 undefined0 undefined
20100 undefined-0.01 undefined-0.01 undefined
20090.02 undefined0 undefined0 undefined
20080 undefined-0.02 undefined-0.01 undefined
20070 undefined-0.02 undefined-0.02 undefined
20060 undefined-0.02 undefined-0.02 undefined
20050 undefined-0.02 undefined-0.01 undefined

Imugene business model

Imugene Ltd is an Australian biotechnology company focused on the development of immunotherapies for various diseases, including cancer and infectious diseases. The company was founded in 2014 and is headquartered in Sydney. Imugene's business model is based on collaboration with academic institutions and other biotechnology companies to identify and develop promising drug candidates. The company also works closely with clinical researchers and physicians to accelerate drug development and ensure they meet patient needs. Imugene specializes in four different areas: oncology, immunology, infectious diseases, and neuroscience. Each area focuses on the development of drugs for specific diseases and medical needs. In the field of oncology, Imugene is focused on developing immunotherapy products for the treatment of breast cancer, colon cancer, lung cancer, and other types of cancer. Immunotherapy aims to strengthen the body's immune system to better destroy cancer cells. In the field of immunology, Imugene is focused on developing immunotherapy products for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immunotherapy aims to modulate the immune system to eliminate disease-causing cells. In the field of infectious diseases, Imugene is focused on developing vaccines and products for the treatment of diseases such as COVID-19, influenza, hepatitis B, and HPV. Vaccines aim to activate the immune system to recognize and destroy pathogens before they can cause harm in the body. In the field of neuroscience, Imugene is focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. These drugs aim to stimulate the brain's neuroprotective mechanisms to reduce nerve damage. Imugene has several promising products in the pipeline that aim to demonstrate the efficacy and safety of immunotherapy and other therapies. The company has already conducted clinical trials for some of these products, while others are still in preclinical development. One of Imugene's key products is HER-Vaxx, a vaccine for the treatment of breast cancer that activates the body's immune system against the HER2 protein, which promotes cancer growth in some individuals. The vaccine has been tested in clinical trials and has shown promising results. Another promising product from Imugene is PD1-Vaxx, a vaccine for the treatment of lung cancer that targets the activation of an important immune cell sensor. Preliminary study results suggest that treatment with PD1-Vaxx is synergistic with checkpoint inhibitors, another type of cancer treatment medication. Imugene is also working on a range of products for the treatment of COVID-19, including IMM-013, a vaccine against SARS-CoV-2, and IMM-036, an antibody against the virus. These products are being tested in preclinical development and are aimed at helping to contain the spread of the pandemic. Overall, Imugene aims to develop innovative drugs for the treatment of various medical needs. The company relies on close collaboration with academic and clinical partners to accelerate drug development and ensure its products meet the highest standards of efficacy and safety. Imugene is one of the most popular companies on Eulerpool.com.

Imugene SWOT Analysis

Strengths

Imugene Ltd has a strong portfolio of innovative biotechnology products, providing them with a competitive advantage in the market. Their products have shown promising results in the treatment of various diseases, positioning the company as a leader in the industry.

Weaknesses

One of the weaknesses of Imugene Ltd is its heavy reliance on external funding for research and development. This raises concerns about the company's financial stability and ability to sustain long-term growth. Additionally, Imugene Ltd may lack the resources and infrastructure compared to larger competitors.

Opportunities

There are several opportunities for Imugene Ltd to capitalize on. The increasing demand for effective biotechnology solutions presents a significant market potential for the company. Moreover, strategic partnerships and collaborations with established pharmaceutical companies can provide access to additional resources and expand Imugene Ltd's market presence.

Threats

Imugene Ltd faces several threats that could impact its operations. Regulatory hurdles and compliance requirements in the biotechnology industry present challenges that may delay product approvals and market entry. Furthermore, intense competition from other biotechnology companies with similar products and technologies can erode Imugene Ltd's market share.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Imugene Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Imugene historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Imugene shares outstanding

The number of shares was Imugene in 2023 — This indicates how many shares 6.276 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Imugene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Imugene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Imugene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Imugene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Imugene.

Imugene latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.01 -0.01  (-8.91 %)2024 Q4
12/31/20230 -0.01  (0 %)2024 Q2
6/30/20230 -0  (0 %)2023 Q4
12/31/20220 -0  (0 %)2023 Q2
6/30/2022-0 -0  (-33.33 %)2022 Q4
12/31/2021-0 -0  (-50 %)2022 Q2
6/30/2021-0 -0  (-50 %)2021 Q4
12/31/2020-0 -0  (0 %)2021 Q2
1

Eulerpool ESG Scorecard© for the Imugene stock

Eulerpool World ESG Rating (EESG©)

37/ 100

🌱 Environment

36

👫 Social

62

🏛️ Governance

12

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees89
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Imugene shareholders

%
Name
Stocks
Change
Date
5.49953 % Hopper (Paul E.)409,071,90609/25/2024
3.91596 % Mann Family291,281,412291,281,4128/26/2023
2.54024 % The Vanguard Group, Inc.188,951,22809/30/2024
1.58638 % Smith (Nicholas)118,000,00008/26/2023
1.47918 % Vanguard Investments Australia Ltd.110,025,86462,7279/30/2024
1.15228 % Chong (Leslie)85,710,4165,793,7507/1/2024
0.81439 % Netwealth Investments Ltd.60,576,704-567,4038/26/2023
0.30921 % SVE Capital Pty. Ltd.23,000,00008/26/2023
0.28216 % Eckstein (Jens W)20,988,095250,0007/1/2024
0.27544 % Russell (Cooper Lesley R)20,488,095250,0007/1/2024
1
2
3
4
5
...
7

Imugene Executives and Management Board

Ms. Leslie Chong

Imugene Chief Executive Officer, Managing Director, Executive Director (since 2015)
Compensation 2.48 M

Dr. Nicholas Ede

Imugene Chief Technology Officer (since 2013)
Compensation 874,912

Dr. Monil Shah

Imugene Chief Business Officer
Compensation 799,197

Mr. Michael Tonroe

Imugene Chief Financial Officer, Company Secretary
Compensation 768,068

Mr. Paul Hopper

(66)
Imugene Executive Chairman of the Board (since 2012)
Compensation 515,227
1
2
3

Imugene Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Citigroup Stock
Citigroup
SupplierCustomer0,710,090,590,620,580,66
Celularity A Stock
Celularity A
SupplierCustomer0,310,25-0,19-0,66-0,39-0,68
1

Most common questions regarding Imugene

What values and corporate philosophy does Imugene represent?

Imugene Ltd represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize cancer treatment through its cutting-edge immunotherapy technologies. Imugene prioritizes scientific expertise and fosters strategic partnerships to advance its pipeline of novel and targeted therapies. The company's commitment to improving treatment outcomes for patients is evidenced by its emphasis on clinical development, rigorous research, and commercialization of innovative products. Imugene's inclusive approach promotes open communication and collaboration among researchers, clinicians, and industry experts, reinforcing its dedication to making a significant impact in the fight against cancer.

In which countries and regions is Imugene primarily present?

Imugene Ltd is primarily present in Australia, United States, and Europe.

What significant milestones has the company Imugene achieved?

Imugene Ltd has achieved several significant milestones. The company successfully completed a Phase 1b study for its HER-Vaxx cancer immunotherapy in gastric cancer patients. Imugene also received approval from the US FDA to initiate its Phase 2 study for HER-Vaxx in gastric cancer. Additionally, Imugene has entered collaborations with renowned academic institutions, including City of Hope, to conduct preclinical and clinical trials for various cancer treatments. The company has made considerable progress in advancing its innovative immunotherapy pipeline, which shows great potential in the field of oncology. Imugene Ltd continues to strive for excellence and breakthroughs in cancer treatments.

What is the history and background of the company Imugene?

Imugene Ltd is a biopharmaceutical company dedicated to developing innovative immunotherapies to treat cancer. Founded in 1983, Imugene has a rich history in the field of oncology research and drug development. The company focuses on creating targeted immunotherapies that harness the power of the immune system to fight cancer cells. Imugene is committed to addressing unmet medical needs and improving patient outcomes. With a strong team of experienced scientists and a robust pipeline of promising drug candidates, Imugene aims to revolutionize cancer treatment and provide hope to patients worldwide. Imugene Ltd continues to strive towards its mission of developing much-needed advancements in the oncology field.

Who are the main competitors of Imugene in the market?

The main competitors of Imugene Ltd in the market include major biopharmaceutical companies such as Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, and Pfizer Inc. These companies also specialize in developing innovative treatments and therapies for various diseases and disorders.

In which industries is Imugene primarily active?

Imugene Ltd is primarily active in the biotechnology industry.

What is the business model of Imugene?

Imugene Ltd is a biotechnology company specializing in the development and commercialization of innovative immunotherapies for the treatment of various cancers. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to create targeted and personalized immunotherapies that activate the body's own immune system to fight cancer. Imugene aims to improve patient outcomes and address the unmet medical needs in oncology by advancing their immunotherapy pipeline. With a focus on developing novel treatments and strategic partnerships, Imugene is dedicated to making a significant impact in the field of cancer immunotherapies.

What is the P/E ratio of Imugene 2024?

The Imugene P/E ratio is -1.7.

What is the P/S ratio of Imugene 2024?

The Imugene P/S ratio is 0.

What is the Quality Investing of Imugene?

The Quality Investing for Imugene is 4/10.

What is the revenue of Imugene 2024?

The revenue cannot currently be calculated for Imugene.

How high is the profit of Imugene 2024?

The Imugene profit is -149.68 M AUD.

What is the business model of Imugene

Imugene Ltd is an Australian biopharmaceutical company that focuses on researching, developing, and marketing innovative therapeutic solutions for the treatment of cancer and infectious diseases. The company uses a unique technology platform to responsibly develop immuno-oncology products. Imugene is headquartered in Sydney, Australia, and has additional offices in the USA and Europe. The four main business areas of Imugene are: 1) Immuno-Oncology Products, 2) Immunomodulating Solutions in Cancer, 3) Infectious Diseases, and 4) Partner Programs. Imugene aims to expand its portfolio of immunotherapeutics through new product development and collaborations. It strives to revolutionize the treatment of cancer and infectious diseases with its unique technology platform and comprehensive portfolio of immunotherapeutics. Imugene is well-positioned to become a leading player in the biopharmaceutical industry with its presence in Australia, the USA, and Europe.

What is the Imugene dividend?

Imugene pays a dividend of 0 AUD distributed over payouts per year.

How often does Imugene pay dividends?

The dividend cannot currently be calculated for Imugene or the company does not pay out a dividend.

What is the Imugene ISIN?

The ISIN of Imugene is AU000000IMU9.

What is the Imugene WKN?

The WKN of Imugene is 891460.

What is the Imugene ticker?

The ticker of Imugene is IMU.AX.

How much dividend does Imugene pay?

Over the past 12 months, Imugene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Imugene is expected to pay a dividend of 0 AUD.

What is the dividend yield of Imugene?

The current dividend yield of Imugene is .

When does Imugene pay dividends?

Imugene pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Imugene?

Imugene paid dividends every year for the past 0 years.

What is the dividend of Imugene?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Imugene located?

Imugene is assigned to the 'Health' sector.

Wann musste ich die Aktien von Imugene kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Imugene from 12/29/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 12/29/2024.

When did Imugene pay the last dividend?

The last dividend was paid out on 12/29/2024.

What was the dividend of Imugene in the year 2023?

In the year 2023, Imugene distributed 0 AUD as dividends.

In which currency does Imugene pay out the dividend?

The dividends of Imugene are distributed in AUD.

All fundamentals about Imugene

Our stock analysis for Imugene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.